Literature DB >> 30201421

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Claire Brittain1, Andrew McCarthy2, Michael C Irizarry3, Dana McDermott4, Kevin Biglan3, Günter U Höglinger5, Stefan Lorenzl6, Teodoro Del Ser7, Adam L Boxer4.   

Abstract

BACKGROUND: Progressive supranuclear palsy (PSP) -Richardson's Syndrome and Corticobasal Syndrome (CBS) are the two classic clinical syndromes associated with underlying four repeat (4R) tau pathology. The PSP Rating Scale is a commonly used assessment in PSP clinical trials; there is an increasing interest in designing combined 4R tauopathy clinical trials involving both CBS and PSP.
OBJECTIVES: To determine contributions of each domain of the PSP Rating Scale to overall severity and characterize the probable sequence of clinical progression of PSP as compared to CBS.
METHODS: Multicenter clinical trial and natural history study data were analyzed from 545 patients with PSP and 49 with CBS. Proportional odds models were applied to model normalized cross-sectional PSP Rating Scale, estimating the probability that a patient would experience impairment in each domain using the PSP Rating Scale total score as the index of overall disease severity.
RESULTS: The earliest symptom domain to demonstrate impairment in PSP patients was most likely to be Ocular Motor, followed jointly by Gait/Midline and Daily Activities, then Limb Motor and Mentation, and finally Bulbar. For CBS, Limb Motor manifested first and ocular showed less probability of impairment throughout the disease spectrum. An online tool to visualize predicted disease progression was developed to predict relative disability on each subscale per overall disease severity.
CONCLUSION: The PSP Rating Scale captures disease severity in both PSP and CBS. Modelling how domains change in relation to one other at varying disease severities may facilitate detection of therapeutic effects in future clinical trials.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corticobasal syndrome; Interactive visualizations; PSP rating scale; Predictive models; Progressive supranuclear palsy

Mesh:

Year:  2018        PMID: 30201421      PMCID: PMC6399076          DOI: 10.1016/j.parkreldis.2018.08.025

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  18 in total

Review 1.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

2.  Prevalence and natural history of progressive supranuclear palsy.

Authors:  L I Golbe; P H Davis; B S Schoenberg; R C Duvoisin
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

3.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

4.  Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.

Authors:  Laurène Leclair-Visonneau; Tiphaine Rouaud; Bérangère Debilly; Franck Durif; Jean-Luc Houeto; Alexandre Kreisler; Luc Defebvre; Estelle Lamy; Christelle Volteau; Jean-Michel Nguyen; Séverine Le Dily; Philippe Damier; Claire Boutoleau-Bretonnière; Pascal Lejeune; Pascal Derkinderen
Journal:  Clin Neurol Neurosurg       Date:  2016-04-27       Impact factor: 1.876

5.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

6.  Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.

Authors:  Maria Stamelou; Alexander Reuss; Ulrich Pilatus; Jörg Magerkurth; Petra Niklowitz; Karla M Eggert; Andrea Krisp; Thomas Menke; Carmen Schade-Brittinger; Wolfgang H Oertel; Günter U Höglinger
Journal:  Mov Disord       Date:  2008-05-15       Impact factor: 10.338

Review 7.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

8.  A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Authors:  Eduardo Tolosa; Irene Litvan; Günter U Höglinger; David Burn; Andrew Lees; María V Andrés; Belén Gómez-Carrillo; Teresa León; Teodoro Del Ser
Journal:  Mov Disord       Date:  2014-02-14       Impact factor: 10.338

9.  Progression of gait, speech and swallowing deficits in progressive supranuclear palsy.

Authors:  Christopher G Goetz; Sue Leurgans; Anthony E Lang; Irene Litvan
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

10.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

View more
  3 in total

Review 1.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

2.  Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.

Authors:  Marta F Pereira; Tim Buchanan; Günter U Höglinger; Marko Bogdanovic; George Tofaris; Simon Prangnell; Nagaraja Sarangmat; James J FitzGerald; Chrystalina A Antoniades
Journal:  BMJ Neurol Open       Date:  2022-01-21

3.  A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy.

Authors:  Lawrence I Golbe; Pamela Ohman-Strickland; Emily B Beisser; Francesca T Elghoul
Journal:  Mov Disord Clin Pract       Date:  2020-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.